Head to Head Contrast: Doximity (NYSE:DOCS) and Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON) and Doximity (NYSE:DOCS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Volatility & Risk

Aclarion has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Doximity has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Earnings & Valuation

This table compares Aclarion and Doximity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	83.88	-$7.23 million	($7.40)	-0.31
Doximity	$644.86 million	7.26	$196.05 million	$0.85	30.92

Doximity has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Aclarion and Doximity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Doximity	4	12	7	2	2.28

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 221.89%. Doximity has a consensus price target of $32.43, indicating a potential upside of 23.40%. Given Aclarion’s higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Doximity.

Profitability

This table compares Aclarion and Doximity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Doximity	25.48%	18.06%	15.40%

Insider & Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 87.2% of Doximity shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 31.8% of Doximity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Doximity beats Aclarion on 13 of the 15 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Doximity

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.